

# 9

## Vitamin B<sub>12</sub>

### SUMMARY

Vitamin B<sub>12</sub> (cobalamin) functions as a coenzyme for a critical methyl transfer reaction that converts homocysteine to methionine and for a separate reaction that converts L-methylmalonyl-coenzyme A (CoA) to succinyl-CoA. The Recommended Dietary Allowance (RDA) for vitamin B<sub>12</sub> is based on the amount needed for the maintenance of hematological status and normal serum vitamin B<sub>12</sub> values. An assumed absorption of 50 percent is included in the recommended intake. The RDA for adults is 2.4 µg/day of vitamin B<sub>12</sub>. Because 10 to 30 percent of older people may be unable to absorb naturally occurring vitamin B<sub>12</sub>, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with vitamin B<sub>12</sub> or a vitamin B<sub>12</sub>-containing supplement. Individuals with vitamin B<sub>12</sub> deficiency caused by a lack of intrinsic factor require medical treatment. The median intake of vitamin B<sub>12</sub> from food in the United States was estimated to be approximately 5 µg/day for men and 3.5 µg/day for women. The ninety-fifth percentile of vitamin B<sub>12</sub> intake from both food and supplements was approximately 27 µg/day. In one Canadian province the mean dietary intake was estimated to be approximately 7 µg/day for men and 4 µg/day for women. There is not sufficient scientific evidence to set a Tolerable Upper Intake Level (UL) for vitamin B<sub>12</sub> at this time.

## BACKGROUND INFORMATION

Cobalamin is the general term used to describe a group of cobalt-containing compounds (corrinoids) that have a particular structure that contains the sugar ribose, phosphate, and a base (5, 6-dimethyl benzimidazole) attached to the corrin ring. Vitamin B<sub>12</sub> can be converted to either of the two cobalamin coenzymes that are active in human metabolism: methylcobalamin and 5-deoxyadenosylcobalamin. Although the preferred scientific use of the term *vitamin B<sub>12</sub>* is usually restricted to cyanocobalamin, in this report, B<sub>12</sub> will refer to all potentially biologically active cobalamins.

In the United States, cyanocobalamin is the only commercially available B<sub>12</sub> preparation used in supplements and pharmaceuticals. It is also the principal form used in Canada (B. A. Cooper, Department of Hematology, Stanford University, personal communication, 1997). Another form, hydroxocobalamin, has been used in some studies of B<sub>12</sub>. Compared with hydroxocobalamin, cyanocobalamin binds to serum proteins less well and is excreted more rapidly (Tudhope et al., 1967).

### *Function*

B<sub>12</sub> is a cofactor for two enzymes: methionine synthase and L-methylmalonyl-CoA mutase. Methionine synthase requires methylcobalamin as a cofactor for the methyl transfer from methyltetrahydrofolate to homocysteine to form methionine and tetrahydrofolate. L-Methylmalonyl-CoA mutase requires adenosylcobalamin to convert L-methylmalonyl-CoA to succinyl-CoA in an isomerization reaction. In B<sub>12</sub> deficiency, folate may accumulate in the serum as a result of slowing of the B<sub>12</sub>-dependent methyltransferase. An adequate supply of B<sub>12</sub> is essential for normal blood formation and neurological function.

### *Physiology of Absorption, Metabolism, Storage, and Excretion*

Small amounts of B<sub>12</sub> are absorbed via an active process that requires an intact stomach, intrinsic factor (a glycoprotein that the parietal cells of the stomach secrete after being stimulated by food), pancreatic sufficiency, and a normally functioning terminal ileum. In the stomach, food-bound B<sub>12</sub> is dissociated from proteins in the presence of acid and pepsin. The released B<sub>12</sub> then binds to R proteins (haptocorrins) secreted by the salivary glands and the gastric mucosa. In the small intestine, pancreatic proteases partially de-

grade the R proteins, releasing B<sub>12</sub> to bind with intrinsic factor. The resulting complex of intrinsic factor and B<sub>12</sub> attaches to specific receptors in the ileal mucosa; after internalization of the complex, B<sub>12</sub> enters the enterocyte. Approximately 3 to 4 hours later, B<sub>12</sub> enters the circulation. All circulating B<sub>12</sub> is bound to the plasma binding proteins—transcobalamin I, II, or III (TCI, TCII, or TCIII). Although TCI binds approximately 80 percent of the B<sub>12</sub> carried in the blood, TCII is the form that delivers B<sub>12</sub> to the tissues through specific receptors for TCII (Hall and Finkler, 1966; Seetharam and Alpers, 1982). The liver takes up approximately 50 percent of the B<sub>12</sub> and the remainder is transported to other tissues.

If there is a lack of intrinsic factor (as is the case in the condition called pernicious anemia), malabsorption of B<sub>12</sub> results; if this is untreated, potentially irreversible neurological damage and life-threatening anemia develop.

The average B<sub>12</sub> content of liver tissue is approximately 1.0 µg/g of tissue in healthy adults (Kato et al., 1959; Stahlberg et al., 1967). Estimates of the average total-body B<sub>12</sub> pool in adults range from 0.6 (Adams et al., 1972) to 3.9 mg (Grasbeck et al., 1958), but most estimates are between 2 and 3 mg (Adams, 1962; Adams et al., 1970; Heinrich, 1964; Reizenstein et al., 1966). The highest estimate found for an individual's total body B<sub>12</sub> store was 11.1 mg (Grasbeck et al., 1958). Excretion of B<sub>12</sub> is proportional to stores (see "Excretion").

### *Absorption*

Studies to measure the actual absorption of B<sub>12</sub> involve whole-body counting of radiolabeled B<sub>12</sub>, counting of radiolabeled B<sub>12</sub> in the stool, or both. No data are available on whether B<sub>12</sub> absorption varies with B<sub>12</sub> status, but fractional absorption decreases as the oral dose is increased (Chanarin, 1979). Total absorption increases with increasing intake. Adams and colleagues (1971) measured fractional absorption of radiolabeled cyanocobalamin and reported that nearly 50 percent was retained at a 1-µg dose, 20 percent at a 5-µg dose, and just over 5 percent at a 25-µg dose. The second of two doses of B<sub>12</sub> given 4 to 6 hours apart is absorbed as well as the first (Heyssel et al., 1966). When large doses of crystalline B<sub>12</sub> are ingested, up to approximately 1 percent of the dose may be absorbed by mass action even in the absence of intrinsic factor (Berlin et al., 1968; Doscherholmen and Hagen, 1957).

*Absorption from Food.* The approximate percentage absorption of B<sub>12</sub> from a few foods is presented in Table 9-1. These values apply to normal, healthy adults. No studies were found on the absorption of B<sub>12</sub> from dairy foods or from red meat other than mutton and liver. The absorption efficiency of B<sub>12</sub> from liver reportedly was low because of its high B<sub>12</sub> content. Although evidence indicates that a B<sub>12</sub> content of 1.5 to 2.5 µg/meal saturates ileal receptors and thus limits further absorption (Scott, 1997), absorption of as much as 7 µg in one subject (18 percent) was reported from a serving of liver paste that contained 38 µg of B<sub>12</sub> (average absorption was 4.1 µg or 11 percent) (Heyssel et al., 1966).

*Assumptions Used in this Report.* Because of the lack of data on dairy foods and most forms of red meat and fish, a conservative adjustment for the bioavailability of naturally occurring B<sub>12</sub> is used in this report. In particular, it is assumed that 50 percent of dietary B<sub>12</sub> is absorbed by healthy adults with normal gastric function. A smaller fractional absorption would apply, however, if a person consumed a large portion of foods rich in B<sub>12</sub>. Different levels of absorption are assumed under various conditions, as shown in Table 9-2. Crystalline B<sub>12</sub> appears in the diet only in foods that have been fortified with B<sub>12</sub>, such as breakfast cereals and liquid meal replacements.

### *Enterohepatic Circulation*

B<sub>12</sub> is continually secreted in the bile. In healthy individuals most of this B<sub>12</sub> is reabsorbed and available for metabolic functions. El Kholty et al. (1991) demonstrated that the secretion of B<sub>12</sub> into the bile averaged  $1.0 \pm 0.44$  nmol/day (1.4 µg/day) in eight cholecystectomized patients, and this represented 55 percent of total corrinoids. If approximately 50 percent of this B<sub>12</sub> is assumed to be

**TABLE 9-1** Percentage Absorption of Vitamin B<sub>12</sub> from Foods by Healthy Adults

Reference	Food	Absorption (%)
Heyssel et al., 1966	Mutton	65
Heyssel et al., 1966	Liver	11
Doscherholmen et al., 1975	Eggs	24-36
Doscherholmen et al., 1978	Chicken	60
Doscherholmen et al., 1981	Trout	25-47

**TABLE 9-2** Assumed Vitamin B<sub>12</sub> Absorption under Different Conditions

Form of Vitamin B <sub>12</sub>	Normal Gastric Function (%)	Pernicious Anemia <sup>a</sup> (%)
Naturally occurring <sup>b</sup>	50	0
Crystalline, low dose (< 5 µg) <sup>b</sup>	60	0
Crystalline, high dose (≥ 500 µg) with water <sup>c</sup>	1	1
Crystalline, high dose with food <sup>c</sup>	0.5	≤ 0.5

<sup>a</sup> A disorder in which lack of intrinsic factor severely limits the absorption of vitamin B<sub>12</sub>.

<sup>b</sup> Heyssel et al. (1966).

<sup>c</sup> Berlin et al. (1968).

reabsorbed, the average loss of biliary B<sub>12</sub> in the stool would be 0.5 nmol/day (0.7 µg/day). Research with baboons (Green et al., 1982) suggests that the form of B<sub>12</sub> present in bile may be absorbed more readily than is cyanocobalamin, but the absorption of both forms was enhanced by intrinsic factor. Both Green and colleagues (1982) and Teo and coworkers (1980) reported data suggesting that bile enhances B<sub>12</sub> absorption. However, in the absence of intrinsic factor, essentially all the B<sub>12</sub> from the bile is excreted in the stool rather than recirculated. Thus, B<sub>12</sub> deficiency develops more rapidly in individuals who have no intrinsic factor or who malabsorb B<sub>12</sub> for other reasons than it does in those who become complete vegetarians and thus ingest no B<sub>12</sub>.

### Excretion

If the circulating B<sub>12</sub> exceeds the B<sub>12</sub> binding capacity of the blood, the excess is excreted in the urine. This typically occurs only after injection of B<sub>12</sub>. The highest losses of B<sub>12</sub> ordinarily occur through the feces. Sources of fecal B<sub>12</sub> include unabsorbed B<sub>12</sub> from food or bile, desquamated cells, gastric and intestinal secretions, and B<sub>12</sub> synthesized by bacteria in the colon. Other losses occur through the skin and metabolic reactions. Fecal (Reizenstein, 1959) and urinary losses (Adams, 1970; Heinrich, 1964; Mollin and Ross, 1952) decrease when B<sub>12</sub> stores decrease. Various studies have indicated losses of 0.1 to 0.2 percent of the B<sub>12</sub> pool per day (Amin et al., 1980; Boddy and Adams, 1972; Bozian et al., 1963; Heinrich, 1964; Heyssel et al., 1966; Reizenstein et al., 1966) regardless of the size of the store, with the 0.2 percent value generally applicable to those with pernicious anemia.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.